Dicot Pharma says three LIB-01 erectile dysfunction trial abstracts win oral slots at SMSNA meeting
Reuters2026/08/19 06:37- Dicot Pharma flagged three LIB-01 abstracts selected for oral presentation at the SMSNA meeting in Orlando on Oct. 8-11, 2026.
- Results have not yet been presented; the data are scheduled for the Innovation Session on Oct. 9.
- Clinical updates point to durable improvements in erectile function from an oral, first-in-class therapy concept with a long duration of action.
- The company also outlined a Phase 2b study design built around LIB-01’s prolonged pharmacodynamic profile, following positive Phase 2a topline results.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Xenia Hôtellerie Solution announces extraordinary shareholder meeting
Community Reacts As Pundit Claims XRP Will Be Priced At $2,953 By Q2 2027
Colgate-Palmolive (CL.US) plans to sell part of its personal care brands, with a total transaction amount possibly exceeding 1.1 billions USD.
According to sources familiar with the matter, Colgate is exploring the sale of some of its mass-market personal care brands. The company currently plans to divest only a few brands within its personal care business, and the combined sale price may exceed 1 billion dollars.
EdiliziAcrobatica announces shareholder meeting notice
Crypto prices
More
